Back to Search Start Over

T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function.

Authors :
Underwood S
Jin J
Shao L
Prochazkova M
Shi R
Song HW
Jin P
Shah NN
Somerville RP
Stroncek DF
Highfill SL
Source :
ImmunoHorizons [Immunohorizons] 2024 Jun 01; Vol. 8 (6), pp. 404-414.
Publication Year :
2024

Abstract

T cell activation is an essential step in chimeric Ag receptor (CAR) T (CAR T) cell manufacturing and is accomplished by the addition of activator reagents that trigger the TCR and provide costimulation. We explore several T cell activation reagents and examine their effects on key attributes of CAR T cell cultures, such as activation/exhaustion markers, cell expansion, gene expression, and transduction efficiency. Four distinct activators were examined, all using anti-CD3 and anti-CD28, but incorporating different mechanisms of delivery: Dynabeads (magnetic microspheres), TransAct (polymeric nanomatrix), Cloudz (alginate hydrogel), and Microbubbles (lipid membrane containing perfluorocarbon gas). Clinical-grade lentiviral vector was used to transduce cells with a bivalent CD19/CD22 CAR, and cell counts and flow cytometry were used to monitor the cells throughout the culture. We observed differences in CD4/CD8 ratio when stimulating with the Cloudz activator, where there was a significant skewing toward CD8 T cells. The naive T cell subset expressing CD62L+CCR7+CD45RA+ was the highest in all donors when stimulating with Dynabeads, whereas effector/effector memory cells were highest when using the Cloudz. Functional assays demonstrated differences in killing of target cells and proinflammatory cytokine secretion, with the highest killing from the Cloudz-stimulated cells among all donors. This study demonstrates that the means by which these stimulatory Abs are presented to T cells contribute to the activation, resulting in differing effects on CAR T cell function. These studies highlight important differences in the final product that should be considered when manufacturing CAR T cells for patients in the clinic.<br /> (Copyright © 2024 The Authors.)

Details

Language :
English
ISSN :
2573-7732
Volume :
8
Issue :
6
Database :
MEDLINE
Journal :
ImmunoHorizons
Publication Type :
Academic Journal
Accession number :
38864817
Full Text :
https://doi.org/10.4049/immunohorizons.2400008